Panmure Gordon Reiterates Hold Rating for AstraZeneca plc (AZN)
AstraZeneca plc (NYSE:AZN) traded down 0.19% during mid-day trading on Friday, hitting $73.05. 1,904,264 shares of the company’s stock traded hands. AstraZeneca plc has a one year low of $48.53 and a one year high of $82.68. The stock has a 50-day moving average of $72.76 and a 200-day moving average of $70.62. The company has a market cap of $92.262 billion and a P/E ratio of 45.66. AstraZeneca plc also was the target of unusually large options trading activity on Thursday. Traders bought 20,242 call options on the stock. This represents an increase of 544% compared to the average daily volume of 3,143 call options.
AstraZeneca plc (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 31st. The company reported $1.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.09 by $0.21. The company had revenue of $6.45 billion for the quarter, compared to the consensus estimate of $6.24 billion. During the same quarter last year, the company posted $1.20 earnings per share. AstraZeneca plc’s revenue was up 3.6% compared to the same quarter last year. On average, analysts predict that AstraZeneca plc will post $4.40 earnings per share for the current fiscal year.
The company also recently announced a semiannual dividend, which is scheduled for Monday, September 15th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.90 per share. This represents a dividend yield of 2.48%. The ex-dividend date is Wednesday, August 13th.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday. Separately, analysts at Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, August 14th. Four research analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $57.00.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Receive News & Ratings for AstraZeneca plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.